Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival.


Journal

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
ISSN: 1744-2818
Titre abrégé: Amyloid
Pays: England
ID NLM: 9433802

Informations de publication

Date de publication:
Jun 2022
Historique:
pubmed: 5 2 2022
medline: 23 6 2022
entrez: 4 2 2022
Statut: ppublish

Résumé

The three main cardiac amyloidosis (CA) types have different progression and prognosis. Little is known about the mode of death (MOD) which is commonly attributed to cardiovascular causes in CA. Improving MOD's knowledge could allow to adapt patient care. This retrospective study describes the MOD that occurred during long-term follow-up in CA patients in light-chain (AL), transthyretin hereditary (ATTRv) or wild-type (ATTRwt). Patients referred to and cared for, at the French referral centre for CA, Henri Mondor Hospital, Créteil between 2010 and 2016 were included. Clinical information surrounding patient deaths were investigated and centrally evaluated by two blinded clinical committees which classified MOD as cardiovascular, non-cardiovascular or unknown and sub-classified it depending on its subtype. From the 566 patients included, 187 had AL, 206 ATTRv and 173 ATTRwt. During the 864 patient-year follow-up, 160 (28%) deaths occurred, with median survival time of 17.3 months (interquartile range 5.1-35.4). The most frequent MOD was cardiovascular (64%) of which worsening heart failure occurred most frequently and for which, 69% were of AL subtype, 79% ATTRv and 76% ATTRwt. Sudden death also occurred more frequently in AL subtype accounting for 29% of AL deaths. Non-cardiovascular MOD occurred in 26% of patients overall. Among these, infection was the most common non-cardiovascular MOD in any type of CA (80%). Mortality is high during natural course of CA and differs between subtypes. The main MOD were worsening heart failure, sudden death and infection, opening room to optimise management.

Sections du résumé

BACKGROUND UNASSIGNED
The three main cardiac amyloidosis (CA) types have different progression and prognosis. Little is known about the mode of death (MOD) which is commonly attributed to cardiovascular causes in CA. Improving MOD's knowledge could allow to adapt patient care.
OBJECTIVE UNASSIGNED
This retrospective study describes the MOD that occurred during long-term follow-up in CA patients in light-chain (AL), transthyretin hereditary (ATTRv) or wild-type (ATTRwt).
MATERIAL AND METHODS UNASSIGNED
Patients referred to and cared for, at the French referral centre for CA, Henri Mondor Hospital, Créteil between 2010 and 2016 were included. Clinical information surrounding patient deaths were investigated and centrally evaluated by two blinded clinical committees which classified MOD as cardiovascular, non-cardiovascular or unknown and sub-classified it depending on its subtype.
RESULTS UNASSIGNED
From the 566 patients included, 187 had AL, 206 ATTRv and 173 ATTRwt. During the 864 patient-year follow-up, 160 (28%) deaths occurred, with median survival time of 17.3 months (interquartile range 5.1-35.4). The most frequent MOD was cardiovascular (64%) of which worsening heart failure occurred most frequently and for which, 69% were of AL subtype, 79% ATTRv and 76% ATTRwt. Sudden death also occurred more frequently in AL subtype accounting for 29% of AL deaths. Non-cardiovascular MOD occurred in 26% of patients overall. Among these, infection was the most common non-cardiovascular MOD in any type of CA (80%).
CONCLUSIONS UNASSIGNED
Mortality is high during natural course of CA and differs between subtypes. The main MOD were worsening heart failure, sudden death and infection, opening room to optimise management.

Identifiants

pubmed: 35114877
doi: 10.1080/13506129.2021.2013193
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

79-91

Auteurs

Mounira Kharoubi (M)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Cardiology, Henri Mondor University Hospital, Creteil, France.
Inserm U955, IMRB, Creteil, France.

Diane Bodez (D)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Cardiology, Henri Mondor University Hospital, Creteil, France.
Inserm U955, IMRB, Creteil, France.
Centre Cardiologique du Nord, Saint Denis, France.

Mélanie Bézard (M)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Cardiology, Henri Mondor University Hospital, Creteil, France.
Inserm U955, IMRB, Creteil, France.

Amira Zaroui (A)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Cardiology, Henri Mondor University Hospital, Creteil, France.
Inserm U955, IMRB, Creteil, France.

Arnault Galat (A)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Cardiology, Henri Mondor University Hospital, Creteil, France.
Inserm U955, IMRB, Creteil, France.

Soulef Guendouz (S)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Cardiology, Henri Mondor University Hospital, Creteil, France.
Inserm U955, IMRB, Creteil, France.

Thierry Gendre (T)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Neurology, Henri Mondor University Hospital, Creteil, France.

Luc Hittinger (L)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Cardiology, Henri Mondor University Hospital, Creteil, France.
Inserm U955, IMRB, Creteil, France.

David Attias (D)

Centre Cardiologique du Nord, Saint Denis, France.

Dania Mohty (D)

Department of Cardiology, Dupuytren University Hospital, Limoges, France.
AL Amyloidosis Referral Center, Dupuytren University Hospital, Limoges, France.

Eric Bergoend (E)

AP-HP, Department of Cardiac Surgery, Henri Mondor University Hospital, Creteil, France.

Emmanuel Itti (E)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Nuclear Medicine, Henri Mondor University Hospital, Creteil, France.

Fabien Lebras (F)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Lymphoid Malignancy Unit, Henri Mondor University Hospital, Creteil, France.

David Hamon (D)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Cardiology, Henri Mondor University Hospital, Creteil, France.
Inserm U955, IMRB, Creteil, France.

Elsa Poullot (E)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Biology-Pathology, Henri Mondor Univ Paris Est Creteil, INSERM, IMRB, Creteil, France.

Valérie Molinier-Frenkel (V)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Biology-Pathology, Henri Mondor Univ Paris Est Creteil, INSERM, IMRB, Creteil, France.
AP-HP, Department of Immunobiology, Henri Mondor University Hospital, Créteil, France.

Nicolas Lellouche (N)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Cardiology, Henri Mondor University Hospital, Creteil, France.
Inserm U955, IMRB, Creteil, France.

Jean-François Deux (JF)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Radiology, Henri Mondor University Hospital, Créteil, France.

Benoit Funalot (B)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Genetic, Henri Mondor Teaching Hospital, Créteil, France.

Pascale Fannen (P)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Genetic, Henri Mondor Teaching Hospital, Créteil, France.

Silvia Oghina (S)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Cardiology, Henri Mondor University Hospital, Creteil, France.
Inserm U955, IMRB, Creteil, France.

Raphael Arrouasse (R)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
Inserm, Clinical Investigations Center 1430, AP-HP, DMU Saphire, Henri Mondor University Hospital, Creteil, France.

Philippe Lecorvoisier (P)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
Inserm, Clinical Investigations Center 1430, AP-HP, DMU Saphire, Henri Mondor University Hospital, Creteil, France.

Sarah Souvannanorath (S)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Referral Center for Neuromuscular Disease Department, Henri Mondor University Hospital, Créteil, France.

Aurelien Amiot (A)

Department of Gastroenterology, Henri Mondor University Hospital, AP-HP, EA7375, University Paris-Est Creteil, Creteil, France.

Emmanuel Teiger (E)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Cardiology, Henri Mondor University Hospital, Creteil, France.
Inserm U955, IMRB, Creteil, France.

Wulfran Bougouin (W)

AP-HP, Centre de Recherche Cardiovasculaire de Paris (PARCC), INSERM U970, Centre d'Expertise Mort Subite (CEMS), Paris Descartes University, Paris, France.
Ramsay Générale de Santé, Hôpital Privé Jacques Cartier, Massy, France.

Thibaud Damy (T)

National Referral Center for Cardiac Amyloidosis, Creteil, France.
GRC Amyloid Research Institute University Paris-Est Creteil INSERM, IMRB, Creteil, France.
AP-HP, Department of Cardiology, Henri Mondor University Hospital, Creteil, France.
Inserm U955, IMRB, Creteil, France.
Inserm, Clinical Investigations Center 1430, AP-HP, DMU Saphire, Henri Mondor University Hospital, Creteil, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH